Market Cap
$180.7M
NAUT
Nautilus Biotechnology, Inc.
$1.81 ▲ +15.28%
Prev close $1.57Market cap$180.7M
ConsensusStrong Buy
12-mo target$3.83 (+111.8%)
▲ Bullish
Analyst conviction 9/10
17 New Institutional Positions6 Institutional Exits Industrials & Manufacturing
Snapshot
The big-picture read on NAUT right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (88%)
Inst. Holders
50 funds
Inst. Value
$48.1M
Inst. Activity
17 buys / 6 sells
Insider Activity
$0.00 buy / $11.8M sell
Insider Net $
-$11.8M
Social Sentiment
43° Neutral
SEC Reports
3
Press Releases
1
Price chart 30d +88.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 short_volume
Short Volume: NAUT — 58.1% short (7.1M / 12.3M)
Short: 7,127,103 | Exempt: 160,324 | TRF Vol: 12,277,373 | Short Ratio: 58.1% | Off-exchange volume
Jun 30, 2026 Inst.
a16z Capital Management, L.L.C. — TRIM
9,063,054 shares ($16.9M)
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
2,687,226 shares ($5.0M)
Jun 18, 2026 Insider
Akinsanya Karen was granted 45,000 shares
Director
Jun 18, 2026 Insider
Posard Matthew L. was granted 45,000 shares
Director
Jun 18, 2026 Insider
Apr 28, 2026 SEC Epperly Melissa B, was granted 45,000 shares
Director
Nautilus Biotechnology reported Q1 2026 EPS of -$0.12, beating consensus of -$0.14 by 17.2%, with revenue still at $0 as
PRESS-RELEASE — Impact 4/10
Nautilus Biotechnology reported Q1 2026 results: net loss of $14.7M improved from $16.6M a year ago, with operating expe
8-K — Impact 4/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
88% rate it Buy or better · 8 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 29, 2026 | Roth Capital | INITIATE | Buy | 56% |
| Sep 9, 2026 | Leerink Partners | INITIATE | Outperform | 49% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Aug 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Jul 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Jun 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% |
Price targets
Where 3 covering analysts think NAUT trades over the next 12 months.
$3.83 +111.8% upside Strong Buy
Current$1.81 Low$3.50 Median$4.00 High$4.00 3 analysts
$3.50$4.00
Analyst rating Strong Buy· 1.0/5 as of Oct 2, 2026
Social media sentiment mood +50.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
43°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
3 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 3 neutral · avg impact 4.0/10.Plus 1 press releases.
NEUTRALPRESS-RELEASE4/10
Nautilus Biotechnology reported Q1 2026 EPS of -$0.12, beating consensus of -$0.14 by 17.2%, with re
Apr 28, 2026
NEUTRAL8-K4/10
Nautilus Biotechnology reported Q1 2026 results: net loss of $14.7M improved from $16.6M a year ago,
Apr 28, 2026
NEUTRAL8-K4/10
Nautilus Biotechnology reported reduced operating expenses and net losses for Q4 and full-year 2025,
Feb 26, 2026
MIXED6/10
Nautilus Biotechnology announced that Baylor College of Medicine has joined its Iterative Mapping Ea
Mar 18, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 29, 2026
short_volume
Short Volume: NAUT — 58.1% short (7.1M / 12.3M)
Short: 7,127,103 | Exempt: 160,324 | TRF Vol: 12,277,373 | Short Ratio: 58.1% | Off-exchange volume (dark pool + OTC)
Sep 16, 2026
short_volume
Short Volume: NAUT — 55.4% short (0.4M / 0.8M)
Short: 427,713 | Exempt: 96 | TRF Vol: 771,472 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
Sep 9, 2026
short_volume
Short Volume: NAUT — 61.5% short (1.6M / 2.6M)
Short: 1,609,069 | Exempt: 2,286 | TRF Vol: 2,617,811 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)
Sep 4, 2026
other
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms
First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential
Aug 31, 2026
short_volume
Short Volume: NAUT — 58.8% short (0.3M / 0.5M)
Short: 303,268 | Exempt: 2,300 | TRF Vol: 515,498 | Short Ratio: 58.8% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.14 | $-0.15–$-0.14 | -30.3% | +4.4% | 0↑ 1↓ | $0.0B | 3 |
| Next Q | $-0.14 | $-0.15–$-0.11 | -24.3% | -24.2% | 0↑ 1↓ | $0.0B | 3 |
| Current FY | $-0.51 | $-0.53–$-0.48 | -9.0% | -1.5% | 1↑ 0↓ | $0.0B | 4 |
| Next FY | $-0.52 | $-0.63–$-0.41 | -1.9% | -0.5% | 1↑ 0↓ | $0.0B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.143 | — |
| 7d ago | $-0.145 | +0.002 |
| 30d ago | $-0.150 | +0.007 |
| 60d ago | $-0.150 | +0.007 |
| 90d ago | $-0.150 | +0.007 |
Institutional ownership
Which big funds own NAUT (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $48.1M total value (25,757,673 shares) as of 2026-Q2. Top holders: a16z, BlackRock,, VANGUARD. Net buying activity: 17 institutions added/increased vs 6 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| a16z Capital Management, L.L.C. | 9,063,054 | $16.9M | 35.2% | TRIM -48.7% |
| BlackRock, Inc. | 2,687,226 | $5.0M | 10.4% | DOUBLED +1331.9% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,549,979 | $4.8M | 9.9% | — |
| CITADEL ADVISORS LLC | 1,896,192 | $3.5M | 7.4% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 1,265,535 | $2.4M | 4.9% | DOUBLED +109.7% |
| Clearstead Advisors, LLC | 892,787 | $1.7M | 3.5% | TRIM -61.7% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 890,949 | $1.7M | 3.5% | — |
| BARCLAYS PLC | 725,321 | $1.4M | 2.8% | DOUBLED +889.2% |
| RENAISSANCE TECHNOLOGIES LLC | 690,514 | $1.3M | 2.7% | DOUBLED +159.9% |
| JPMORGAN CHASE & CO | 614,177 | $1.1M | 2.3% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| a16z Capital Management, L.L.C. | TRIM | 17,653,917 | 9,063,054 | -48.7% | $16.9M |
| BlackRock, Inc. | DOUBLED | 187,671 | 2,687,226 | +1331.9% | $5.0M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 603,524 | 1,265,535 | +109.7% | $2.4M |
| Clearstead Advisors, LLC | TRIM | 2,329,784 | 892,787 | -61.7% | $1.7M |
| BARCLAYS PLC | DOUBLED | 73,325 | 725,321 | +889.2% | $1.4M |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 265,700 | 690,514 | +159.9% | $1.3M |
| STATE STREET CORP | DOUBLED | 216,270 | 559,508 | +158.7% | $1.0M |
| DIMENSIONAL FUND ADVISORS LP | ADD | 329,123 | 475,844 | +44.6% | $889.3K |
| NORTHERN TRUST CORP | DOUBLED | 107,011 | 381,234 | +256.3% | $712.9K |
| Qube Research & Technologies Ltd | DOUBLED | 79,623 | 257,346 | +223.2% | $481.2K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 13 transactions. Net -$11.8M — $0.00 bought, $11.8M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 18, 2026 | Akinsanya Karen | Director | AWARD | 45,000 | — | — |
| Jun 18, 2026 | Posard Matthew L. | Director | AWARD | 45,000 | — | — |
| Jun 18, 2026 | Epperly Melissa B, | Director | AWARD | 45,000 | — | — |
| Jun 18, 2026 | McIlwain Matthew S | Director | AWARD | 45,000 | — | — |
| Jun 18, 2026 | NAZEM FARZAD | Director | AWARD | 45,000 | — | — |
| Jun 2, 2026 | AH Equity Partners Bio II, L.L.C. | 10%+ Owner | SELL | 4,615,974 | $2.35 | $10.8M |
| Jun 2, 2026 | AH Equity Partners Bio II, L.L.C. | 10%+ Owner | SELL | 384,026 | $2.35 | $902.5K |
| Mar 2, 2026 | Weld Gwen E | Chief People Officer | AWARD | 160,000 | — | — |
| Mar 2, 2026 | Mallick Parag | Chief Scientist | AWARD | 280,000 | — | — |
| Mar 2, 2026 | Suzuki Kentaro | Chief Marketing Officer | AWARD | 160,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for NAUT.
Shares short
4,082,014
Settlement Sep 15, 2026
Change vs prior
+7.0%
Semi-monthly cycle
Days to cover
3.2
At avg daily volume
Of shares outstanding
≈3.2%
Estimate — not % of float
All NAUT filing & press-release reports (4)
- PRESS-RELEASE reportApr 28, 2026
- 8-K reportApr 28, 2026
- PRESS-RELEASE reportMar 18, 2026
- 8-K reportFeb 26, 2026